title: A cross-sectional survey of the association between bilateral topical prostaglandin analogue use and ocular adnexal features.
abstract: We studied the relation between prostaglandin analogue use and ocular adnexal features. We used a prospective, cross-sectional study involving 157 current, 15 past, and 171 never users of prostaglandin analogues. Patients 50 years of age or older and without conditions affecting ocular adnexal anatomy underwent glaucoma medication use history, external digital photography and systematic external adnexal exam. Two masked readers assessed the digital photos for upper lid dermatochalasis and lower lid steatoblepharon using a validated grading scheme. Another masked clinical examiner also assessed upper lid ptosis, levator muscle function, and inferior scleral show. We performed ordinal logistic regression analysis accounting for multiple covariates to assess the relation between prostaglandin analogue use and adnexal features. Multivariable analyses indicated there was a 230-fold increased risk of incremental involution of dermatochalasis (odds ratio (OR) = 2.30; 95% confidence interval (CI) 1.43-3.69; p = 5.44E-04) and a 249-fold increased risk of incremental loss of lower lid steatoblepharon (OR = 2.49; 95% CI, 1.54-4.03; p= 1.98E-04) associated with current prostaglandin analogue use (bimatoprost 0.03%, travoprost 0.005%, or latanoprost 0.004%) versus prostaglandin analogue never or past users. Upper lid ptosis (OR = 4.04; 95% CI, 2.43-6.72; p = 7.37E-08), levator dysfunction (OR = 7.51; 95% CI, 3.39-16.65; p = 6.74E-07) and lower lid retraction (OR = 2.60; 95% CI, 1.58-4.28; p = 1.72E-04) were highly associated with current prostaglandin analogue use versus prostaglandin analogue never or past users. The associations between prostaglandin analogue use and deepening of the upper lid sulci and between prostaglandin analogue use and loss of inferior periorbital fat are confirmed in this multivariable analysis. The associations between prostaglandin analogue use and levator muscle dysfunction and between prostaglandin analogue use and upper lid ptosis represent significant side effects that could impact visual function in glaucoma patients.
authors: Department of Ophthalmology, Boston University School of Medicine, Boston, Massachusetts, United States of America. mshah@bu.edu
authors: Mamta
authors: M
authors: Shah
authors: Grace
authors: G
authors: Lee
authors: Daniel R
authors: DR
authors: Lefebvre
authors: Benjamin
authors: B
authors: Kronberg
authors: Stephanie
authors: S
authors: Loomis
authors: Stacey C
authors: SC
authors: Brauner
authors: Angela
authors: A
authors: Turalba
authors: Douglas J
authors: DJ
authors: Rhee
authors: Suzanne K
authors: SK
authors: Freitag
authors: Louis R
authors: LR
authors: Pasquale
mesh_terms: D000577:Amides / Q000009:adverse effects / Q000627:therapeutic use; D000069580:Bimatoprost; D003008:Cloprostenol / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D005143:Eyelids / Q000002:abnormalities / Q000187:drug effects; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D000077338:Latanoprost; D015999:Multivariate Analysis; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use; D011465:Prostaglandins, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D012868:Skin Abnormalities / Q000139:chemically induced*; D050151:Subcutaneous Fat / Q000002:abnormalities / Q000187:drug effects; D000069557:Travoprost
chemical_list: D000577:Amides; D011461:Prostaglandins F, Synthetic; D011465:Prostaglandins, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D000069580:Bimatoprost; D000069557:Travoprost
references: Nepal J Ophthalmol. 2012 Jan-Jun;4(1):150-61
references: 22344013
references: Orbit. 2010 Dec;29(6):357-9
references: 21158579
references: Ophthalmic Plast Reconstr Surg. 2008 Jul-Aug;24(4):302-7
references: 18645437
references: Cutan Ocul Toxicol. 2010 Sep;29(3):212-6
references: 20670089
references: Dermatol Clin. 1992 Jul;10(3):505-12
references: 1617809
references: Jpn J Ophthalmol. 2011 Jan;55(1):22-7
references: 21331688
references: Surv Ophthalmol. 2008 Nov;53 Suppl1:S93-105
references: 19038628
references: Jpn J Ophthalmol. 2011 Nov;55(6):600-4
references: 21953485
references: Ophthalmic Plast Reconstr Surg. 2012 Mar-Apr;28(2):e42-4
references: 21659917
references: Invest Ophthalmol Vis Sci. 1997 Dec;38(13):2772-80
references: 9418730
references: Clin Ophthalmol. 2012;6:739-46
references: 22654501
references: J Glaucoma. 2013 Oct-Nov;22(8):626-31
references: 22936280
references: Optom Vis Sci. 2011 Sep;88(9):1140-4
references: 21666524
references: Ophthalmology. 2004 May;111(5):1029-34
references: 15121384
references: Optom Vis Sci. 2004 Aug;81(8):574-7
references: 15300114
references: Invest Ophthalmol Vis Sci. 2007 Aug;48(8):3677-82
references: 17652738
references: Ophthalmology. 2005 Apr;112(4):694-704
references: 15808264
references: BMJ Open. 2012 Aug 23;2(4):
references: 22918671
references: Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5259-65
references: 19443729
references: Klin Monbl Augenheilkd. 2008 May;225(5):443-5
references: 18454393
references: Curr Med Res Opin. 2010 Mar;26(3):511-28
references: 20014995
references: Surv Ophthalmol. 2008 Nov;53 Suppl1:S107-20
references: 19038618
references: Br J Ophthalmol. 2001 Jan;85(1):99-101
references: 11133723